Back to Report Store Home

Hepatitis Drug Development Pipeline Review, 2018

  • Published: Jun-2018
  • Report Code: GBIHC039IDB
  • Report Format: pdf

Description

This report provides an overview of the pipeline landscape for hepatitis infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, hepatitis B, hepatitis D and hepatitis E, and features dormant and discontinued products.

Hepatitis refers to inflammation of the liver and is most commonly caused by viral infections. Hepatitis A and E are typically caused by ingestion of contaminated food or water. Symptoms of hepatitis A infection include fatigue, nausea and vomiting, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes. Risk factors include a weakened immune system and use of injected or non-injected illicit drugs. Symptoms of hepatitis E include yellowing of the skin, dark urine, fever, fatigue, joint pain, nausea, a loss of appetite and pain in the abdomen.

Hepatitis B and hepatitis D infection typically occur as a result of contact with infected body fluids. Transmission of hepatitis B can occur via sexual contact, injection drug use or transfusions of contaminated blood and blood products. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes, dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Hepatitis D infection only occurs in persons previously infected with hepatitis B, as the hepatitis D virus can only replicate in the presence of hepatitis B. The co-infection of hepatitis B and hepatitis D is associated with greater disease severity than hepatitis B infection alone.

Companies operating in this pipeline space include Cadila Healthcare and Chongqing Zhifei Biological Products.

Scope

  • Which companies are the most active within each pipeline?

  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons To Buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards